Medicare Enrolled
Dr. James Lee, MD
Medical Oncology · Moorestown, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Lee from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Lee?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Lee
Dr. James Lee is a medical oncology specialist in Moorestown, NJ, with 20 years of NPI registration. Based on federal Medicare data, Dr. Lee performed 21,184 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Lee received a total of $1,277 from 23 pharmaceutical and/or device companies across 87 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Lee is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 22% volume in NJ
$1,277 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗21,184
Medicare services
Top 22% in NJ for medical oncology
Not available
Unique patients (not deduplicated)
$16
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
7,400 | $6 | $46 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
4,000 | $6 | $29 |
| Iron infusion (Monoferric) | 3,100 | $17 | $71 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,858 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 620 | $1 | $107 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
593 | $103 | $230 |
| Pegfilgrastim-cbqv injection An injection of pegfilgrastim-cbqv, a biosimilar medication, administered at a dose of 0.5 mg. |
492 | $109 | $879 |
| Injection, granisetron hydrochloride, 100 mcg | 380 | $0 | $12 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
311 | $12 | $82 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
231 | $115 | $609 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
194 | $147 | $310 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
186 | $13 | $89 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
103 | $25 | $134 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
100 | $64 | $200 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
81 | $25 | $144 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
69 | $1 | $6 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
62 | $56 | $257 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
57 | $29 | $124 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
55 | $57 | $269 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
50 | $66 | $158 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
46 | $134 | $351 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
43 | $1 | $14 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
41 | $145 | $420 |
| New patient office visit, complex (60-74 min) | 31 | $178 | $443 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
30 | $99 | $231 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
27 | $67 | $156 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
24 | $23 | $88 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
16.8% high complexity
78.1% medium
5.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$1,277
Total received (2018-2024)
Avg $255/year across 5 years
Top 42% in NJ for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
23
Companies
87
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$36
2021
$87
2020
$29
2019
$584
2018
$542
Payments by company (2024)
GENZYME CORPORATION
$21
PFIZER INC.
$14
Top 3 companies account for 100.0% of 2024 payments
All-time payments by company (2018-2024) ›
Lilly USA, LLC
$144
Amgen Inc.
$121
Janssen Biotech, Inc.
$119
Novartis Pharmaceuticals Corporation
$101
E.R. Squibb & Sons, L.L.C.
$94
AstraZeneca Pharmaceuticals LP
$70
Celgene Corporation
$67
Takeda Pharmaceuticals U.S.A., Inc.
$62
Seattle Genetics, Inc.
$53
GENZYME CORPORATION
$50
Genentech USA, Inc.
$45
Puma Biotechnology, Inc.
$44
Bayer HealthCare Pharmaceuticals Inc.
$42
Merck Sharp & Dohme Corporation
$42
Gilead Sciences, Inc.
$42
Foundation Medicine, Inc.
$38
Eisai Inc.
$29
AbbVie, Inc.
$28
PFIZER INC.
$26
Bioventus LLC
$21
AMAG Pharmaceuticals, Inc.
$14
Heron Therapeutics, Inc.
$13
Rigel Pharmaceuticals, Inc.
$12
Top 3 companies account for 30.1% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · Abraxane · Alecensa · CABLIVI · CINVANTI · CYRAMZA · DARZALEX · DUPIXENT · FERAHEME · FOUNDATIONONE · GELSYN 3 · Halaven · IMBRUVICA · IMFINZI · INLYTA · KANJINTI · KEYTRUDA · KISQALI · LIBTAYO · MEKINIST · MVASI · NINLARO · NURTEC ODT · Nerlynx · Neulasta · Nplate · OPDIVO · Perjeta · Pomalyst · Prolia · RETEVMO · Revlimid · SANDOSTATIN · SPRYCEL · Stivarga · TAGRISSO · Tavalisse · VERZENIO · Vectibix · Venclexta · Vitrakvi
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Medical oncologists in nearby ZIP areas
109
County median income
$105,271
Nearest hospital to ZIP centroid (approximate)
VIRTUA WILLINGBORO HOSPITAL
4.4 mi
4.4 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Lee is a mixed practice specialist, with above-average Medicare volume (top 22% in NJ), with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Lee experienced with epoetin alfa injection (procrit) for anemia?
Based on Medicare claims data, Dr. Lee performed 7,400 epoetin alfa injection (procrit) for anemia services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Lee receive payments from pharmaceutical companies?
Yes. Dr. Lee received a total of $1,277 from 23 companies across 87 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Lee's costs compare to other medical oncologists in Moorestown?
Dr. Lee's average Medicare payment per service is $16. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Lee) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Moorestown
Browse medical oncologists in Moorestown ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in NJ
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in NJ
Which NJ medical oncologists receive the most from drug and device companies.
By company
Lilly USA, LLC Payments to Doctors
See all physicians who received payments from Lilly USA, LLC.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology